IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, reported a double-digit growth in revenue for the fourth quarter of fiscal 2025.
- IDEXX posted revenues of $1.09 billion for the fourth quarter of 2025, up 14% from last year
- Companion Animal Group revenue increased 15%, and Water revenue grew 12% year-over-year
- On an organic basis, sales grew 12% in Q4, with Companion Animal Group sales growing 13% and Water revenue rising 10% YoY
- Earnings, on a per-share basis, were $3.08 in the fourth quarter, an increase of 18% as reported and 17% on a comparable basis
- For fiscal 2026, the management expects revenue to be in the range of $4.63 billion to $4.72 billion, representing a 7.6-9.6% YoY increase
- Full-year organic revenue is expected to increase in the range of 7% to 9%
- The guidance for FY26 earnings per share is between $14.29 and $14.80, representing a 9-13% YoY increase
- On a comparable basis, full-year earnings are expected to grow between 10% and 14%